NANCY FELTY MORIN MD
Prescription History 1992765713
Internal Medicine - Hematology & Oncology in Wakefield, RI
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for NANCY FELTY MORIN MD, an active Hematology & Oncology specialist practicing in Wakefield, RI. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 141 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 34 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other RI PrescribersVs. RI Avg |
|---|---|---|---|
| EliquisApixaban | 34 | $893.82 | ▼ Less than typical |
About Eliquis: Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. Show more ▾ With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood. An antithrombotic agent. In 2024, this provider wrote 34 Medicare prescriptions for Eliquis, about a third of the volume of the typical Rhode Island prescriber of this medication (101.4). Medicare paid an average of $893.82 per fill, versus $746.72 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average RI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 51.8 30-Day Fills standardized to 30-day supplies 1,554 Days of Medication total across all patients in 2024 | |||
| Anastrozole | 21 | $33.11 | ▼ Less than typical |
About Anastrozole: Anastrozole is used to treat breast cancer in women after menopause. Show more ▾ Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women. In 2024, this provider wrote 21 Medicare prescriptions for Anastrozole, about a third of the volume of the typical Rhode Island prescriber of this medication (65.6). Medicare paid an average of $33.11 per fill, versus $19.91 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average RI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 63 30-Day Fills standardized to 30-day supplies 1,890 Days of Medication total across all patients in 2024 | |||
| BrukinsaZanubrutinib | 17 | $14,076.59 | ▼ Less than typical |
About Brukinsa: This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma). Show more ▾ Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. A Bruton tyrosine kinase (BTK) inhibitor for treatment of Waldenstrom macroglobulinemia. In 2024, this provider wrote 17 Medicare prescriptions for Brukinsa, about 63% of the volume of the typical Rhode Island prescriber of this medication (26.9). Medicare paid an average of $14,076.59 per fill, versus $12,893.67 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average RI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 17 30-Day Fills standardized to 30-day supplies 510 Days of Medication total across all patients in 2024 | |||
| JakafiRuxolitinib Phosphate | 16 | $9,740.90▼ below RI avg | ▼ Less than typical |
About Jakafi: This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). Show more ▾ It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system). In 2024, this provider wrote 16 Medicare prescriptions for Jakafi, about 63% of the volume of the typical Rhode Island prescriber of this medication (25.5). Medicare paid an average of $9,740.90 per fill, versus $16,230.84 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average RI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the RI average for this medication. 16 30-Day Fills standardized to 30-day supplies 480 Days of Medication total across all patients in 2024 | |||
| Allopurinol | 14 | $7.90▼ below RI avg | ▼ Less than typical |
About Allopurinol: Allopurinol is used to treat gout and certain types of kidney stones. Show more ▾ It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems. A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. In 2024, this provider wrote 14 Medicare prescriptions for Allopurinol, about a third of the volume of the typical Rhode Island prescriber of this medication (47). Medicare paid an average of $7.90 per fill, versus $11.93 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average RI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the RI average for this medication. 31.1 30-Day Fills standardized to 30-day supplies 932 Days of Medication total across all patients in 2024 | |||
| Acyclovir | 13 | $13.03▼ below RI avg | ▼ Less than typical |
About Acyclovir: Acyclovir is used to treat infections caused by certain types of viruses. Show more ▾ It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections. A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. In 2024, this provider wrote 13 Medicare prescriptions for Acyclovir, about half the volume of the typical Rhode Island prescriber of this medication (22.7). Medicare paid an average of $13.03 per fill, versus $15.00 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average RI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the RI average for this medication. 13 30-Day Fills standardized to 30-day supplies 330 Days of Medication total across all patients in 2024 | |||
| Exemestane | 13 | $522.80 | ▼ Less than typical |
About Exemestane: This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Show more ▾ Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age. A hormonal antineoplastic agent. In 2024, this provider wrote 13 Medicare prescriptions for Exemestane, about half the volume of the typical Rhode Island prescriber of this medication (22.4). Medicare paid an average of $522.80 per fill, versus $206.89 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average RI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 40.3 30-Day Fills standardized to 30-day supplies 1,210 Days of Medication total across all patients in 2024 | |||
| Hydroxyurea | 13 | $16.68▼ below RI avg | ▼ Less than typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2024, this provider wrote 13 Medicare prescriptions for Hydroxyurea, about a third of the volume of the typical Rhode Island prescriber of this medication (39.9). Medicare paid an average of $16.68 per fill, versus $27.49 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average RI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the RI average for this medication. 23.1 30-Day Fills standardized to 30-day supplies 694 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for NANCY FELTY MORIN MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology & Oncology prescribing approach at this Wakefield, RI practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among RI prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
